The effects of skin-to-skin contact, application site washing, and sunscreen use on the pharmacokinetics of estradiol from a metered-dose transdermal spray

Menopause

Volumn 16, Issue 1, 2009, Pages 177-183

  Schumacher, Robert J ^a,b   Gattermeir, David J ^b   Peterson, Craig A ^c   Wisdom, Charlene ^c   Day, Wesley W ^c  

^a MAYO CLINIC   (United States)

^b KV Pharmaceutical Company   (United States)

^c Menlo Park and VIVUS   (United States)

Author keywords

Estradiol; Hormone therapy; Menopause; Transdermal pharmacokinetics

Indexed keywords

ESTRADIOL; PARACETAMOL; SUNSCREEN; SOAP;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BODY PAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PAIN; POSTMENOPAUSE; TIME TO MAXIMUM PLASMA CONCENTRATION; AGED; BLOOD; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; SKIN ABSORPTION;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ESTRADIOL; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTMENOPAUSE; SKIN ABSORPTION; SOAPS; SUNSCREENING AGENTS;

EID: 64049116515     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31817e2c77     Document Type: Article

References (26)

1. Rapkin AJ. Vasomotor symptoms in menopause: physiologic condition and central nervous system approaches to treatment. Am J Obstet Gynecol 2007;196:97-106.
2. Avis NE, Crawford SL, McKinlay SM. Psychosocial, behavioral, and health factors related to menopause symptomatology. Womens Health 1997;3:103-120.
3. Guthrie JR, Dennerstein L, Taffe JR, Donnelly V. Health care-seeking for menopausal problems. Climacteric 2003;6:112-117.
4. Bobula JD. Vasomotor symptoms and quality of life (QoL) in postmenopausal women. Value Health 2003;6:707.
5. Brazier JE, Roberts J, Platts M, Zoellner YF. Estimating a preference-based index for a menopause specific health quality of life questionnaire. Health Qual Life Outcome 2005;3:13-22.
6. Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993;307:836-840.
7. Carpenter JS. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on the quality of life following breast cancer. J Pain Symptom Manage 2001;22:979-989.
8. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Maturitas 2005;50:91-97.
9. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207-1218.
10. Sikon A, Thacker HL. Treatment options for menopausal hot flashes. Cleve Clin J Med 2004;71:578-582.
11. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
12. Place VA, Powers M, Darley PE. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol 1985;152:1092-1099.
13. Steingold KA, Laufer L, Chetkowski RJ, et al. Treatment of hot flashes with transdermal estradiol administration. J Clin Endocrinol Metab 1985;61:627-632.
14. Ibarra de Palacios P, Schmidt G, Sergejew T, et al. Comparative study to evaluate skin irritation and adhesion of Estradot and Climera in healthy postmenopausal women. Climacteric 2002;5:383-389.
15. Utian WH. Transdermal estradiol overall safety profile. Am J Obstet Gynecol 1987;156:1335-1338.
16. Baker VL. Alternatives to oral estrogen replacement. Obstet Gynecol Clin North Am 1994;21:217-297.
17. Scott RT, Ross B, Anderson C. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991;77:758-764.
18. Morgan TM, O'Sullivan HMM, Reed BL, Finnin BC. Transdermal delivery of estradiol in postmenopausal women with a novel topical aerosol. J Pharm Sci 1998;87:1226-1228.
19. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res 2000;17:1278-1283.
20. Sivanandy MS, Masimasi N, Thacker HL. Newer hormonal therapies: lower doses; oral, transdermal, and vaginal formulations. Cleve Clin J Med 2007;74:369-375.
21. Yasui T, Uemura H, Takikawa M, Irahara M. Hormone replacement therapy in postmenopausal women. J Med Invest 2003;50:136-145.
22. Choi BG, McLaughlin MA. Why men's hearts break: cardiovascular effects of sex steroids. Endocrinol Metab Clin North Am 2007;36:365-377.
23. Aksglaede L, Juul A, Leffers H, Skakkebaek NE, Andersson AM. The sensitivity of the child to sex steroids: possible impact of exogenous estrogens. Hum Reprod Update 2006;12:341-349.
24. Delanoe D, Fougeyrollas B, Meyer L, Thomneau P. Androgenization of female partners of men on medroxyprogesterone acetate-percutaneous testosterone contraception. Lancet 1984;1:276-277.
25. Schaison G, Couzinet B. Percutaneous dihydrotestosterone treatment. In: Nieschlag E, Behre HM eds. Testosterone: Action, Deficiency, Substitution, 2nd ed. Berlin: Springer, 1998:423-436.
26. Pont AR, Charron AR, Wilson RM, Brand RM. Effects of active sunscreen ingredient combinations on the topical penetration of the herbicide 2,4-dichlorophenoxyacetic acid. Toxicol Ind Health 2003;19:1-8.